2-Phenyl-4-acylbenzofuran compounds, their preparation and uses

The 2-phenyl-4-acylbenzofuran compounds developed by optimizing the Bysspectin A structure have solved the problems of difficult extraction and separation and complex synthesis of hCES2A inhibitors in the prior art, achieving efficient inhibition of hCES2A, reducing the side effects of cancer treatment, and providing a simple preparation method.

CN117986215BActive Publication Date: 2026-11-10INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202211359718.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-02
Publication Date
2026-11-10
Estimated Expiration
2042-11-02

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit human carboxylesterase 2A (hCES2A), leading to intestinal side effects caused by cancer treatment, such as delayed diarrhea. Furthermore, existing inhibitors are difficult to extract and separate, and their synthesis processes are complex.

Method used

Develop 2-phenyl-4-acylbenzofuran compounds and their pharmaceutically acceptable salts. By optimizing the structure of Bysspectin A, a selective hCES2A inhibitor is provided. The synthesis is carried out using a Sonogashira coupling cyclization reaction, which is a simple method.

Benefits of technology

The new compounds exhibit significantly enhanced hCES2A inhibitory activity, with some compounds showing nearly 10-fold increased activity and lower toxicity, making them suitable for preventing and alleviating side effects caused by gastrointestinal diseases and cancer treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117986215B_ABST
    Figure CN117986215B_ABST
Patent Text Reader

Abstract

This invention belongs to the field of pharmaceutical technology and relates to 2-phenyl-4-acylbenzofuran compounds with hCES2A inhibitory activity as shown in general formula I, methods for preparing compositions thereof, and their pharmaceutical uses, specifically their use in the preparation of drugs for treating and / or preventing diseases (diarrhea, diarrheal side effects caused by cancer treatment) related to hCES2A inhibitory activity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to 2-substituted phenylbenzofuran compounds or pharmaceutically acceptable salts, their preparation methods, and their pharmaceutical uses. Specifically, it relates to new compounds, novel pharmaceutical effects, and their application in the prevention or relief of side effects caused by gastrointestinal diseases and cancer treatments, belonging to the field of innovative drug research technology. Background Technology

[0002] Carboxylesterases (CEs) are important serine hydrolases widely found in bacteria and the human body. They effectively catalyze the hydrolysis of various esters and amides, as well as drugs (including prodrugs), into their respective free acids. Generally, CEs are believed to play a protective role, cleaving endogenous substrates and exogenous compounds into less toxic hydrolysates for detoxification. This inference is supported to some extent by their expression patterns in higher organisms. In higher organisms, they are often found in tissues potentially exposed to pathogens (such as the liver, kidneys, small intestine, and lung epithelium); they also participate in cholesterol homeostasis and fatty acid metabolism, thereby affecting lipid and glucose homeostasis.

[0003] Human carboxylesterases (hCEs) are a class of hydrolytic enzymes in the human body responsible for the endogenous metabolism of esters. They have been approved by the FDA as a major class of phase I drug-metabolizing enzymes and are drug targets. There are two main subtypes of hCEs: human carboxylesterase 1 (hCES1A) and human carboxylesterase 2 (hCES2A). They exhibit significant differences in tissue distribution and substrate preference. Generally, hCES1 is primarily expressed in the liver, with lower expression in the intestine, kidney, lung, testis, heart, adipocytes, monocytes, and macrophages. hCES1 tends to hydrolyze ester substrates with small hydroxyl groups and large acyl groups, such as enalapril and clopidogrel, as well as illicit drugs like heroin and cocaine. In contrast, hCES2A is expressed at relatively high levels in the small intestine and colon, and this enzyme tends to hydrolyze ester substrates with large hydroxyl groups and small acyl groups, such as irinotecan, flutamide, capecitabine, and prasugrel. Irinotecan is a prodrug requiring activation by carboxylesterase 2 (hCES2A). Upon hydrolysis, it releases the topoisomerase I inhibitor 7-ethyl-10-hydroxycamptothecin (SN-38), and is widely used in the treatment of advanced colorectal cancer. However, excessive accumulation of SN-38 in the intestinal mucosa can lead to delayed diarrhea and even death. Therefore, combining irinotecan with a specific hCES2A inhibitor in clinical applications may reduce its intestinal side effects. Flutamide is a nonsteroidal anti-androgen drug used to treat prostate cancer. It is metabolized by CYP1A and hCES2A to 2-hydroxyflutamide and 5-amino-2-nitrotrifluorotoluene (FLU-1), respectively. The hydrolytic metabolite FLU-1 is further metabolized to the hepatotoxic N-hydroxyFLU-1. Therefore, hCES2A plays a crucial role in the development of various anticancer drug toxicities, making the development of selective inhibitors of hCES2A urgently needed.

[0004] Bysspectin A, a natural product, was discovered in 2018 by Professor Lin Sheng's research group at the Institute of Materia Medica, Chinese Academy of Medical Sciences, from traditional Chinese medicine. Edgeworthia chrysantha Endophytic fungi of leaves Byssochlamys spectabilis A novel diketone derivative was isolated from [the study]. Its structural features include a 2-substituted benzofuran core and two long octone substituents. It exhibits good selective inhibition of hCES2A (IC50). 50=2.01 μM (Eur. J. Med. Chem., 2018, 145, 717-725). Due to the difficulty in extracting and separating this compound, its total synthesis was first reported by Professor Xie Ping's research group at the Institute of Materia Medica, Chinese Academy of Medical Sciences in 2019 (Tetrahedron, 2019, 75, 3101-3107). Subsequently, they optimized the structure, and the optimized compound hCES2A showed superior inhibitory activity compared to the lead compound Bysspectin A (application number: 202210173634.1). Summary of the Invention

[0005] The technical problem solved by the present invention is to provide 2-phenyl-4-acylbenzofuran compounds as shown in general formula I, their preparation methods, pharmaceutical compositions, and their use in treating gastrointestinal diseases and side effects caused by cancer treatment.

[0006] To solve the technical problem of this invention, the present invention provides the following technical solution: The first aspect of the present invention is to provide a compound as shown in general formula I and a pharmaceutically acceptable salt thereof:

[0007] Including any of its tautomer forms, where: R1 is independently selected from C1-16 straight-chain or branched alkyl groups; R2 is independently selected from hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen, nitro, cyano, carboxyl, and C1-4 ester groups; R3 is selected independently. 、 COOR7 ; R4 is independently selected from hydrogen, C1-10 alkyl, C1-10 alkoxy, halogen, nitro, cyano, carboxyl, and C1-4 ester groups; R5 and R6 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , , , , , , , , , , , , ; R7 is independently selected from hydrogen and C1-10 alkyl groups; R8 is independently selected from hydrogen, C1-10 alkyl, and C1-10 haloalkyl; Halogens are represented by fluorine, chlorine, bromine, and iodine.

[0008] Wherein, R1 is independently selected from C1-14 straight-chain or branched alkyl groups; R2 is independently selected from hydrogen, C1-8 alkyl, C1-8 alkoxy, halogen, nitro, cyanocarboxyl, and C1-4 ester groups; R3 is independently selected from… COOR7 R4 is independently selected from hydrogen, C1-8 alkyl, C1-8 alkoxy, halogen, nitro, cyano, carboxyl, and C1-4 ester groups; R5 and R6 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , , , , , , , , , , , , R7 is independently selected from hydrogen and C1-8 alkyl; R8 is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl. Halogens are represented by fluorine, chlorine, bromine, and iodine.

[0009] Preferably, R1 is independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, tert-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, n-octyl, 2-methylheptyl, 3-methylheptyl, 4-methylheptyl, 2 2-Dimethylhexyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,3,4-Trimethylbutyl, n-Nonyl, 2-Methyloctyl, 3-Methyloctyl, 4-Methyloctyl, 2,2-Dimethylheptyl, 2,3-Dimethylhexyl, 2,4-Dimethylhexyl, 2,5-Dimethylhexyl, 2,3,4-Trimethylpentyl, 2,3,5-Trimethylpentyl, n-Decyl, 2-Methyldecyl, 3-Methyldecyl, 4-Methyldecyl R2 is selected independently from hydrogen, 5-methyldecyl, 2,2-dimethyloctyl, 2,3-dimethyloctyl, 2,4-dimethyloctyl, 2,5-dimethyloctyl, 2,6-dimethyloctyl, 2,7-dimethyloctyl, 2,3,4-trimethylheptyl, 2,3,5-trimethylheptyl, 2,3,6-trimethylheptyl, 3,4,5-trimethylheptyl, 3,4,6-trimethylheptyl, 2,3,4,5-tetramethylhexyl, undecyl, dodecyl; Ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, ptert-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, 2-methylbutoxy, ptert-pentoxy, n-hexyloxy, 2-methylpentoxy, 3-methylpentoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy;R3 is independently selected from N,N-dimethylcarbamoyloxy, N-methyl-N-ethylcarbamoyloxy, N,N-diethylcarbamoyloxy, N-methyl-N-propylcarbamoyloxy, N-methyl-N-isopropylcarbamoyloxy, N-methyl-N-butylcarbamoyloxy, N-methyl-N-isobutylcarbamoyloxy, N-ethyl-N-propylcarbamoyloxy, N-ethyl-N-isopropylcarbamoyloxy, N-ethyl-N-butylcarbamoyloxy N-ethyl-N-isobutylcarbamoyloxy, N-propyl-N-butylcarbamoyloxy, N-propyl-N-isobutylcarbamoyloxy, N-butyl-N-isobutylcarbamoyloxy, N,N-dibutylcarbamoyloxy, N,N-diisobutylcarbamoyloxy, 4-morpholinocarbamoyloxy, 1-pyrrolidinecarbamoyloxy, carboxyl group, methyl formate, ethyl formate, propyl formate, isopropyl formate, butyl formate, isobutyl formate, Amino, methoxyformamide, ethoxyformamide, propoxyformamide, isopropoxyformamide, butoxyformamide, isobutoxyformamide, 2-chloroethoxyformamide, 2-chloropropoxyformamide, 3-chloropropoxyformamide, 2-chlorobutoxyformamide, 3-chlorobutoxyformamide, 4-chlorobutoxyformamide; R4 is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl. 2-Methyl-butyl, pteropentyl, n-hexyl, 2-methyl-pentyl, 3-methyl-pentyl, 2,2-dimethyl-butyl, 2,3-dimethyl-butyl, methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-methyl-butoxy, pteropentyl, n-hexyloxy, 2-methyl-pentoxy, 3-methyl-pentoxy, 2,2-dimethyl-butoxy, 2,3-dimethyl-butoxy, halogen, nitro, cyano; R5 and R6 are independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , , , , , , , , , , R7 is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, p-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl; R8 is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, p-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 2-chloroethyl, 2-chloropropyl, 3-chloropropyl, 2-chlorobutyl, 3-chlorobutyl, 4-chlorobutyl.

[0010] The preferred compound is selected from

[0011]

[0012] The second aspect of the present invention is to provide a method for preparing the compound described in the first aspect: Fragment A preparation: Compound III was obtained by coupling commercially available compound II with trimethylsilylacetylene; fragment A was obtained by deprotecting compound III from TMS.

[0013] i. Coupling reaction; ii. Deprotection; wherein R3 and R4 are defined as in any one of claims 1-3; Fragment B preparation: Compound V was obtained by iodination of commercially available compound IV. Compound V was obtained by oxidation of compound V. Compound VI was demethylated to obtain compound VII. Compound VII was protected by hydroxyl group to obtain compound VIII. Compound VIII was given an alkyl side chain by Grignard reaction to obtain compound IX. Compound IX was oxidized to obtain compound X. Compound X was deprotected to obtain fragment B.

[0014] i. Iodination reaction; ii. Oxidation reaction; iii. Demethylation; iv. Adding a protecting group; v. Grignard reaction; vi. Oxidation reaction; vii. Deprotection. Wherein R1 and R2 are defined as in any one of claims 1-3; R9 is methyl, ethyl, triethylsilyl, tert-butyldimethylsilyl, triphenylsilyl, or (trimethylsilyl)ethoxymethyl; Synthesis of I: Compound I was obtained from fragments A and B via a Sonogashira coupling cyclization reaction;

[0015] i. Sonogashira coupling cyclization reaction; wherein R1, R2, R3, R4 are defined as in any one of claims 1-3.

[0016] A third aspect of the present invention is to provide a pharmaceutical composition comprising a preventive and / or therapeutically effective amount of the above-mentioned 2-phenyl-4-acylbenzofuran compound, and optionally a pharmaceutically acceptable carrier and / or excipients.

[0017] In this invention, depending on the route of administration, the pharmaceutical composition of the 2-phenyl-4-acylbenzofuran compound may be in the following dosage forms: solution, suspension, emulsion, pill, capsule, powder, controlled release or sustained release formulation.

[0018] The 2-phenyl-4-acylbenzofuran compound pharmaceutical compositions of the present invention can be formulated by known methods and administered to subjects via several routes, including but not limited to parenteral, oral, topical, intradermal, intramuscular, intraperitoneal, subcutaneous, intravenous, and intranasal routes.

[0019] The 2-phenyl-4-acylbenzofuran compound pharmaceutical compositions of the present invention can optionally be formulated by any conventional method using one or more pharmaceutically acceptable carriers and / or excipients. Thus, 2-substituted phenylbenzofuran compounds and their pharmaceutically acceptable salts can be specifically formulated for inhalation or blowing (through the mouth or nose) or for oral, sublingual, parenteral, or rectal administration.

[0020] Pharmaceutical compositions of 2-phenyl-4-acylbenzofuran compounds can also be in the form of solutions, suspensions, emulsions, pills, capsules, powders, controlled-release or sustained-release formulations. These formulations will contain a therapeutically effective amount of the 2-substituted phenylbenzofuran compound, preferably in a purified form, and an appropriate carrier to provide a suitable form of administration to the patient.

[0021] The fourth aspect of this invention is to provide the compounds described in the first aspect of this invention, or their pharmaceutically acceptable salts, for the prevention, relief, and / or treatment of side effects caused by gastrointestinal diseases and cancer treatment. Any 2-substituted phenylbenzofuran compounds and their salts used for the prevention, relief, and / or treatment of side effects caused by gastrointestinal diseases and cancer treatment fall within the scope of protection of this invention.

[0022] In this invention, the prevention, relief and / or treatment of side effects caused by gastrointestinal diseases and cancer treatment are selected from those that inhibit the activity of hCES2A.

[0023] In this invention, the purified form of the 2-phenyl-4-acylbenzofuran compound refers to a substantially pure 2-phenyl-4-acylbenzofuran compound, particularly with a purity greater than 80%, preferably greater than 85%, particularly preferably greater than 90%, and even more preferably greater than 95%. The purity range of the purified form of the 2-phenyl-4-acylbenzofuran compound can be 90-96%.

[0024] Beneficial technical effects: Based on previous research results, the inventors discovered that the new compounds obtained by further structural optimization of Bysspectin A derivatives have significantly enhanced hCES2A inhibitory activity compared with previous Bysspectin A derivatives, with some compounds showing an activity enhancement of nearly 10 times.

[0025] The new Bysspectin A derivative, general formula I, is a novel monomeric compound with advantages such as low toxicity and simple preparation process. It has excellent application and development prospects and is an ideal new compound for the prevention, relief and / or treatment of side effects caused by gastrointestinal diseases and cancer treatment. It can be applied to the preparation of drugs and health products. Attached Figure Description

[0026] Figure 1 The inhibitory activity curves of the most preferred compounds 1-22 against hCES2A, among which... Figure 1 A- Figure 1 V corresponds to the inhibitory activity curves of the most preferred compounds 1-22 against hCES2A. Detailed Implementation Preparation Example Preparation of intermediate 25-51:

[0027] Methyl 2-iodobenzoate (2 g, 7.6 mmol) was dissolved in 20 mL of anhydrous tetrahydrofuran and placed in a 100 mL two-necked flask. Ar was used to replace the solution three times. Then, bis(triphenylphosphine)palladium(II) chloride (106 mg, 0.15 mmol), cuprous iodide (58 mg, 0.3 mmol), triethylamine (3.8 mL), and trimethylsilylacetylene (5.3 mL) were added sequentially, followed by Ar replacement three times. The mixture was stirred at 50 °C for 5 h. The reaction mixture was monitored by TLC until complete. The reaction was quenched with 0.5 M HCl. The mixture was separated, and the aqueous phase was extracted with DCM. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The mixture was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 97:3) to give compound 25 (1.7 g of yellow oil, 96% yield).

[0028] 1H NMR (400 MHz, CDCl3) δ 7.89 (dd, J = 7.8, 1.3 Hz, 1H), 7.57 (dd, J= 7.9, 1.1 Hz, 1H), 7.43 (td, J = 7.6, 1.4 Hz, 1H), 7.35 (td, J = 7.6, 1.4Hz, 1H), 3.91 (s, 3H), 0.27 (s, 9H).

[0029] Following the synthetic method of compound 25, compound 26 (1.69 g of yellow oil, 95% yield) was prepared from compound methyl 2-iodo-4-methylbenzoate (2 g, 7.2 mmol).

[0030] 1 H NMR (400 MHz, CDCl3) δ 7.70 (s, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.25-7.21 (m, 1H), 3.91 (s, 3H), 2.36 (s, 3H), 0.26 (s, 9H).

[0031] Compound 27 (1.45 g yellow solid, 83% yield) was prepared from compound 2-iodo-4-methylaniline (2 g, 8.6 mmol) using the same method as compound 25.

[0032] 1 H NMR (400 MHz, CDCl3) δ 7.12 (dd, J = 1.4, 0.7 Hz, 1H), 6.92 (ddd, J =8.2, 2.1, 0.7 Hz, 1H), 6.61 (d, J = 8.3 Hz, 1H), 4.10 (br., 2H), 2.19 (s,3H), 0.26 (s, 9H).

[0033] Compound 25 (100 mg, 0.43 mmol) was dissolved in 3 mL of methanol and placed in a 25 mL single-necked flask. Potassium carbonate (6 mg, 0.043 mmol) was added, and the mixture was stirred at room temperature for 1.5 h. The reaction was monitored by TLC (petroleum ether: ethyl acetate = 10:1) to ensure complete reaction. The solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 150:1) to give compound 28 (63 mg of yellow oil, 91% yield).

[0034] 1 H NMR (400 MHz, CDCl3) δ 7.93 (dd, J = 7.8, 0.8 Hz, 1H), 7.62 (dd, J= 7.9, 1.2 Hz, 1H), 7.47 (td, J = 7.6, 1.5 Hz, 1H), 7.39 (td, J = 7.6, 1.4Hz, 1H), 3.92 (s, 3H), 3.39 (s, 1H).

[0035] Following the synthetic method of compound 28, compound 29 (1.11 g of yellow oil, 93% yield) was prepared from compound 26 (1.69 g, 6.9 mmol).

[0036] 1 H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 7.51 (d, J = 7.7 Hz, 1H), 7.33– 7.26 (m, 1H), 3.92 (s, 3H), 3.33 (s, 1H), 2.39 (s, 3H).

[0037] Following the synthetic method of compound 28, compound 30 (yellow oil 856 mg, yield 92%) was prepared from compound 27 (1.45 g, 7.1 mmol).

[0038] 1 H NMR (400 MHz, CDCl3) δ 7.14 (d, J = 2.1 Hz, 1H), 6.96 (dd, J = 8.2,2.1 Hz, 1H), 6.62 (d, J = 8.2 Hz, 1H), 4.11 (br., 2H), 3.36 (s, 1H), 2.21 (s,3H).

[0039] m-Methoxybenzyl alcohol (5 g, 36 mmol) was dissolved in 55 mL of anhydrous diethyl ether and placed in a 500 mL three-necked flask. Ar was used to replace the solution three times. The temperature of the reaction solution was lowered to 0 °C, and n-BuLi (1.6 M, 49.5 mL, 79.2 mmol) was slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 3.5 h. Iodine (9.41 g, 37.08 mmol) was dissolved in 100 mL of anhydrous diethyl ether and added dropwise to the reaction solution. The mixture was stirred at room temperature for 15 min, and the reaction was monitored by TLC to ensure complete reaction of the starting materials. The reaction was quenched by adding an ammonia-ammonium chloride buffer (pH=8). The mixture was separated, and the aqueous phase was extracted with methyl tert-butyl ether. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 15:1) to give compound 31 (6 g white solid, yield 63%).

[0040] 1 H NMR (400 MHz, CDCl3) δ 7.32 (t, J = 7.6 Hz, 1H), 7.08 (dd, J = 7.4, 1.3Hz, 1H), 6.78 (dd, J = 8.2, 1.4 Hz, 1H), 4.72 (s, 2H), 3.90 (s, 3H).

[0041] 2-Methyl-5-methoxybenzoic acid (1 g, 6 mmol) was dissolved in 10 mL of ultra-dry tetrahydrofuran and placed in a 100 mL three-necked flask. Ar was used for purging three times. The reaction solution was cooled to 0 °C, and borane tetrahydrofuran (1 M, 10 mL, 10 mmol) was added dropwise. The reaction solution was brought to room temperature and stirred for 12 h. TLC was used to monitor the reaction until complete. 1 N HCl was added to the reaction solution and stirred for 5 min. The mixture was separated, and the organic phase was extracted with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 20:1) to give compound 32 (900 mg of colorless oil, 99% yield).

[0042] 1 H NMR (400 MHz, CDCl3) δ 7.06 (d, J = 8.3 Hz, 1H), 6.95 (d, J = 2.8 Hz, 1H), 6.74 (dd, J= 8.3, 2.8 Hz, 1H), 4.60 (s, 2H), 3.77 (s, 3H), 2.57 (br.,1H), 2.23 (s, 3H).

[0043] Following the synthetic method of compound 31, compound 33 (525 mg of yellow oil, 33% yield) was prepared from compound 32 (833 mg, 5.5 mmol).

[0044] 1 H NMR (400 MHz, CDCl3) δ 7.11(d, J = 8.3 Hz, 1H), 6.68 (d, J = 8.3 Hz,1H), 4.87 (s, 2H), 3.86 (s, 3H), 2.45 (s, 3H), 2.05 (br., 1H).

[0045] Compound 31 (6 g, 22 mmol) was dissolved in 60 mL of dichloromethane in a 250 mL single-necked flask. The reaction solution was cooled to 0 °C, and Dess-Martin oxidant (11.6 g, 27 mmol) was added. The mixture was stirred at 0 °C for 1 h, and the reaction was monitored by TLC until the starting material was fully reacted. The reaction solution was filtered through diatomaceous earth, and the reaction was quenched by adding saturated sodium thiosulfate / saturated sodium bicarbonate (1:1) and stirring for 20 min. The aqueous phase was separated, and the organic phases were combined and washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether / ethyl acetate = 30:1) to give compound 34 (5.7 g white solid, 97% yield).

[0046] 1 H NMR (400 MHz, CDCl3) δ 10.19 (s, 1H), 7.50 (dd, J = 7.6, 1.3 Hz, 1H), 7.39 (t, J = 7.9 Hz, 1H), 7.05 (dd, J = 8.1, 1.3 Hz, 1H), 3.95 (s, 3H).

[0047] Following the synthetic method of compound 34, compound 35 (395 mg white solid, 80% yield) was prepared from compound 33 (500 mg, 1.8 mmol).

[0048] 1 H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.87(d, J = 8.4 Hz, 1H), 3.90 (s, 3H), 2.47 (s, 3H).

[0049] Compound 34 (2 g, 7.6 mmol) was dissolved in 20 mL of anhydrous dichloromethane and placed in a 100 mL two-necked flask. Ar was used for purging three times. The reaction solution was cooled to 0 °C, and 1 M boron tribromide (dissolved in ultra-dry dichloromethane) (1 M, 19 mL, 19 mmol) was added dropwise. After the addition was complete, the reaction solution was brought to room temperature and stirred for 4 h. TLC was used to monitor the reaction until complete. The reaction mixture was quenched with distilled water, separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 2:1) to give compound 36 (1.2 g of pale yellow solid, yield 64%).

[0050] 1 H NMR (400 MHz, CDCl3) δ 10.03 (s, 1H), 7.46 (dd, J = 7.5, 1.6 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.26 (dd, J = 8.1, 1.6 Hz, 1H), 5.82 (s, 1H).

[0051] Following the synthetic method of compound 36, compound 37 (yellow oil, 272 mg, yield 80%) was prepared from compound 35 (366 mg, 1.33 mmol).

[0052] 1 H NMR (400 MHz, CDCl3) δ 10.22 (s, 1H), 7.13 (d, J = 8.3 Hz, 1H), 7.08(d, J = 8.3 Hz, 1H), 5.75 (s, 1H), 2.51 (s, 3H).

[0053] Compound 36 (1.18 g, 4.7 mmol) was dissolved in 12 mL of anhydrous dichloromethane and placed in a 50 mL two-necked flask. Ar was used for purging three times. The reaction solution was cooled to 0 °C, and N,N-diisopropylethylamine and (trimethylsilyl)ethoxymethyl chloride were added dropwise. The mixture was stirred at 0 °C for 5 min, then the reaction solution was brought to room temperature and stirred for 2 h. TLC was used to monitor the reaction until complete. The reaction was quenched by adding saturated sodium bicarbonate solution. The mixture was separated, and the aqueous phase was extracted with dichloromethane. The combined organic phases were washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether:dichloromethane = 1.5:1) to give compound 38 (1.7 g of pale yellow solid, 99% yield).

[0054] 1 H NMR (400 MHz, CDCl3) δ 10.17 (s, 1H), 7.52 (dd, J = 7.3, 1.8 Hz, 1H),7.38 – 7.33 (m, 1H), 7.31 (dd, J = 8.0, 1.8 Hz, 1H), 5.34 (s, 2H), 3.81 (t, J =8.4 Hz, 2H), 0.95 (t, J = 8.4 Hz, 2H), -0.003 (s, 9H).

[0055] Compound 39 (colorless oil 390 mg, yield 98%) was prepared from compound 37 (266 mg, 1.01 mmol) using the same synthetic method as compound 38.

[0056] 1 H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 7.13 (d, J = 1.9 Hz, 2H), 5.29(s, 2H), 3.85 – 3.75 (m, 2H), 2.48 (s, 3H), 1.01 – 0.88 (m, 2H), -0.003 (s,9H).

[0057] Compound 38 (80 mg, 0.21 mmol) was dissolved in 3 mL of anhydrous diethyl ether in a 25 mL two-necked flask. The mixture was purged three times with Ar, and the temperature of the reaction solution was lowered to 0 °C. A 2 M solution of magnesium octyl bromide in tetrahydrofuran (0.16 mL) was added dropwise, and the mixture was stirred at 0 °C for 0.5 h. TLC showed that the starting material reacted completely. The reaction solution was quenched by adding saturated ammonium chloride solution. The mixture was separated, and the aqueous phase was extracted with methyl tert-butyl ether. The combined organic phases were dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 97:3) to give compound 40 (96 mg of colorless oil, 93% yield).

[0058] 1 H NMR (400 MHz, CDCl3) δ 7.25 – 7.21 (m, 1H), 7.14 (dd, J = 7.7, 1.5Hz, 1H), 6.95 (dd, J = 8.0, 1.5 Hz, 1H), 5.25 (s, 2H), 4.97 (dd, J = 8.4, 3.9 Hz,1H), 3.83 – 3.73 (m, 2H), 3.59 (t, J = 6.7 Hz, 1H), 1.80 – 1.67 (m, 2H), 1.59 –1.52 (m, 2H), 1.25 (m, 10H), 0.98 – 0.89 (m, 2H), 0.85 (t, J =4.4 Hz, 3H), -0.03 (s, 9H).

[0059] Following the synthetic method of compound 40, compound 41 (1.2 g of yellow oil, yield 54%) was prepared by reacting compound 38 (1.83 g, 4.8 mmol) with a tetrahydrofuran solution of hexyl magnesium bromide (1 M, 5.8 mmol).

[0060] 1 H NMR (500 MHz, CDCl3) δ 7.24 (d, J = 8.2 Hz, 1H), 7.14 (d, J = 7.6Hz, 1H), 6.95 (d, J = 8.0 Hz, 1H), 5.26 (s, 2H), 4.98 (d, J = 9.2 Hz, 1H),3.78 (t, J= 6.4 Hz, 2H), 1.94 (s, 1H), 1.80 – 1.69 (m, 1H), 1.60 (m, 1H), 1.52(s, 1H), 1.51 – 1.37 (m, 2H), 1.33 (m, 2H), 1.29 – 1.21 (m, 2H), 0.93 (t, J =6.4 Hz, 2H), 0.85 (t, J = 5.2 Hz, 3H), -0.03 (s, 9H).

[0061] Following the synthetic method of compound 40, compound 42 (colorless oil 248 mg, yield 60%) was prepared by reacting compound 39 (337 mg, 0.86 mmol) with a tetrahydrofuran solution of hexyl magnesium bromide (1 M, 1 ml, 1 mmol).

[0062] 1 H NMR (500 MHz, CDCl3) δ 7.04 (d, J = 8.4 Hz, 1H), 6.86 (d, J = 8.3 Hz,1H), 5.36 (br., 1H), 5.24 (s, 2H), 3.80 (t, J = 6.4 Hz, 2H), 2.47 (s, 3H), 1.95(s, 1H), 1.76 (m, 1H), 1.63 – 1.55 (m, 1H), 1.38 – 1.24 (m, 8H), 0.96 (t, J =6.8 Hz, 2H), 0.89 (t, J = 6.7 Hz, 3H), 0.01 (s, 9H).

[0063] Following the synthetic method of compound 40, compound 43 (1.2 g of yellow oil, 52% yield) was prepared by reacting compound 38 (2.1 g, 5.5 mmol) with a tetrahydrofuran solution of propylmagnesium bromide (2 M, 6.7 mmol).

[0064] 1H NMR (400 MHz, CDCl3) δ 7.34 – 7.23 (m, 1H), 7.17 (dd, J = 7.7, 1.5Hz, 1H), 6.98 (dd, J = 8.1, 1.5 Hz, 1H), 5.29 (s, 2H), 5.03 (dd, J = 8.3, 3.9Hz, 1H), 3.87 – 3.76 (m, 2H), 2.04 (br., 1H), 1.81 – 1.38 (m, 4H), 0.97 (m,5H), 0.001 (s, 9H).

[0065] Compound 40 (90 mg, 0.18 mmol) was dissolved in 3 mL of anhydrous dichloromethane in a 25 mL single-necked flask. The reaction solution was cooled to 0 °C, and Dess-Martin reagent (93 mg, 0.22 mmol) was added. The mixture was stirred for 5 min, and then the reaction was brought to room temperature and stirred for 30 min. The reaction mixture was monitored by TLC until the starting material was completely reacted. The reaction solution was filtered through diatomaceous earth, and the reaction was quenched by adding saturated sodium thiosulfate / saturated sodium bicarbonate (1:1) and stirring for 20 min. The aqueous phase was separated, and the organic phases were combined and washed with saturated brine and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed by vacuum distillation, and the solution was purified by silica gel column chromatography (petroleum ether: dichloromethane = 1:1) to give compound 44 (70 mg of colorless oil, 80% yield).

[0066] 1 H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.8 Hz, 1H), 7.10 (dd, J = 8.3,1.4 Hz, 1H), 6.86 (dd, J = 7.5, 1.4 Hz, 1H), 5.30 (s, 2H), 3.80 (t, J = 6.4 Hz, 2H), 2.85 (t, J = 7.4 Hz, 2H), 1.76 – 1.67 (m, 2H), 1.42 – 1.34 (m, 2H), 1.30 – 1.20 (m, 8H), 0.95 (t, J = 6.4 Hz, 2H), 0.87 (t, J = 6.7 Hz, 3H), -0.00 (s,9H).

[0067] Following the synthetic method of compound 44, compound 45 (yellow oil, 926 mg, 96% yield) was prepared from compound 41 (970 mg, 2.09 mmol).

[0068] 1 H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.8 Hz, 1H), 7.11 (dd, J = 8.3,1.4 Hz, 1H), 6.87 (dd, J = 7.5, 1.4 Hz, 1H), 5.31 (s, 2H), 3.80 (t, J = 6.8 Hz, 2H), 2.86 (t, J = 7.4 Hz, 2H), 1.72 (p, J = 7.5 Hz, 2H), 1.55 (s, 1H), 1.38(m, 2H), 1.31 (m, 3H), 0.96 (t, J = 6.4 Hz, 2H), 0.89 (t, J = 5.6 Hz, 3H), 0.01(s, 9H).

[0069] Following the synthetic method of compound 44, compound 46 (223 mg of yellow oil, 94% yield) was prepared from compound 42 (240 mg, 0.5 mmol).

[0070] 1 H NMR (500 MHz, CDCl3) δ 7.08 (d, J = 8.4 Hz, 1H), 6.95 (d, J = 8.4 Hz,1H), 5.25 (s, 2H), 3.78 (t, J = 6.8 Hz, 2H), 2.80 (t, J = 6.8 Hz, 2H), 2.18 (s,3H), 1.76 (p, J = 7.4 Hz, 2H), 1.40 (m, 2H), 1.34 – 1.22 (m, 4H), 0.94 (t, J =6.8 Hz, 2H), 0.89 (t, J =5.2 Hz, 3H), -0.00 (s, 9H).

[0071] Following the synthetic method of compound 44, compound 47 (yellow oil 860 mg, yield 86%) was prepared from compound 43 (1.01 g, 2.39 mmol).

[0072] 1 H NMR (400 MHz, CDCl3) δ 7.30 (dd, J = 8.3, 7.5 Hz, 1H), 7.11 (dd, J= 8.3, 1.4 Hz, 1H), 6.87 (dd, J = 7.5, 1.4 Hz, 1H), 5.31 (s, 2H), 3.85 – 3.75(m, 2H), 2.85 (t, J = 7.3 Hz, 2H), 1.76 (h, J = 7.4 Hz, 2H), 1.01 (t, J = 7.4Hz, 3H), 0.98 – 0.92 (m, 2H), 0.04 (s, 9H).

[0073] Compound 44 (100 mg, 0.2 mmol) was dissolved in methanol / tetrahydrofuran (1:1) (3 ml) in a single-necked flask. A methanol solution of H₂SO₄ (0.2 ml H₂SO₄ dissolved in 6 ml methanol) was added with stirring, and the mixture was stirred at room temperature for 3 h. The reaction mixture was monitored by TLC until complete. The reaction solution was cooled to 0 °C, quenched with saturated sodium bicarbonate solution, and separated. The aqueous phase was extracted with ethyl acetate, and the organic phases were combined, washed with saturated brine, and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed under reduced pressure, and purified by silica gel column chromatography (petroleum ether:dichloromethane = 1.5:1) to give compound 48 (67 mg of yellow oil, 93% yield).

[0074] 1 H NMR (400 MHz, CDCl3) δ 7.30 – 7.21 (m, 1H), 7.10 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 7.5 Hz, 1H), 3.37 (s, 1H), 2.87 (t, J = 7.3 Hz, 2H), 1.71 (p, J = 7.3Hz, 2H), 1.43 – 1.07 (m, 10H), 0.88 (t, J = 6.8 Hz, 3H).

[0075] Following the synthetic method of compound 48, compound 49 (colorless oil 545 mg, yield 91%) was prepared from compound 45 (837 mg, 1.81 mmol).

[0076] 1 H NMR (400 MHz, CDCl3) δ 7.25 (t, J = 7.2 Hz, 1H), 7.06 (dd, J = 8.1,1.5 Hz, 1H), 6.94 (dd, J = 7.4, 1.5 Hz, 1H), 5.95 (s, 1H), 2.87 (t, J = 7.6 Hz,2H), 1.74 – 1.62 (m, 2H), 1.41 – 1.20 (m, 6H), 0.88 (t, J = 6.8 Hz, 3H).

[0077] Following the synthetic method of compound 48, compound 50 (colorless oil, 216 mg, 99% yield) was prepared from compound 46 (294 mg, 0.62 mmol).

[0078] 1 H NMR (500 MHz, CDCl3) δ 7.05 (d, J = 8.1 Hz, 1H), 6.89 (d, J = 8.5 Hz,1H), 5.37 (s, 1H), 2.78 (t, J = 7.5 Hz, 2H), 2.19 (s, 3H), 1.76 (p, J = 7.5 Hz,2H), 1.40 (m, 2H), 1.33 (m, 4H), 0.90 (t, J = 5.6 Hz, 3H).

[0079] Following the synthetic method of compound 48, compound 51 (colorless oil 545 mg, yield 94%) was prepared from compound 47 (800 mg, 1.9 mmol).

[0080] 1H NMR (400 MHz, CDCl3) δ 7.25 (dd, J = 8.2, 7.5 Hz, 1H), 7.07 (dd, J= 8.1, 1.5 Hz, 1H), 6.95 (dd, J = 7.5, 1.5 Hz, 1H), 6.27 (br., 1H), 2.87 (t,J = 7.3 Hz, 2H), 1.76 (m, 2H), 1.00 (t, J = 7.4 Hz, 3H); Preparation of Examples 1-23: Example 1: Preparation of Compound 1

[0081] Compound 48 (87 mg, 0.56 mmol) was dissolved in 8 mL of anhydrous toluene and placed in a 50 mL three-necked flask. Ar was used for purging three times. [Cu(phen)(PPh3)2]NO3 (46 mg, 0.056 mmol) and Cs2CO3 (332 mg, 1.02 mmol) were added sequentially, followed by Ar purging three times. Then, 8 mL of anhydrous toluene solution of compound 28 (200 mg, 0.56 mmol) was added with stirring, followed by Ar purging three times. The reaction temperature was raised to 110 °C, and the mixture was refluxed and stirred for 5 h. The reaction mixture was monitored by TLC to ensure complete reaction. The reaction solution was cooled to room temperature, filtered, and the solvent was removed under reduced pressure. The solution was purified by silica gel column chromatography (petroleum ether: dichloromethane = 1.5:1) to give compound 1 (97 mg of pale yellow oil, yield 44%).

[0082] 1 H NMR (400 MHz, CDCl3) δ 7.84 (dd, J = 7.7, 0.9 Hz, 1H), 7.79 (dd, J= 7.8, 1.3 Hz, 1H), 7.76 (dd, J = 7.7, 1.4 Hz, 1H), 7.74 (d, J = 0.9 Hz, 1H), 7.65 (dt, J = 8.1, 0.9 Hz, 1H), 7.57 (td, J = 7.6, 1.4 Hz, 1H), 7.47 (td, J =7.6, 1.3 Hz, 1H), 7.35 (t, J = 7.9 Hz, 1H), 3.82 (s, 3H), 3.06 (t, J = 7.4Hz, 2H), 1.80 (m, 2H), 1.41 – 1.23 (m, 10H), 0.89 (t, J = 7.2 Hz, 3H);13 C NMR(100 MHz, CDCl3) δ 201.1, 169.2, 157.5, 155.9, 131.3, 131.2, 130.2, 129.7,129.5, 129.2, 128.5, 124.8, 123.8, 115.6, 106.0, 52.6, 39.5, 32.0, 29.6,29.6, 29.3, 24.7, 22.8, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 25 H 29 O4:393.20604;Found: 393.20630. Example 2 Preparation of Compound 2

[0083] Compound 1 (65 mg, 0.17 mmol) was dissolved in 10 mL of acetone:water (5:1). The reaction solution was cooled to 0 °C, and 0.2 mL of 3 N NaOH was added with stirring. The mixture was stirred at room temperature for 2 h. The reaction was monitored by TLC until the starting material was completely reacted. 1 N HCl was added to the reaction solution to neutralize the NaOH, and the pH was adjusted to 4-5. The mixture was separated, and the aqueous phase was extracted with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered, the solvent was removed by vacuum distillation, and the solution was purified by silica gel column chromatography (petroleum ether:ethyl acetate = 5:1) to give compound 2 (50 mg of yellow oil, yield 78.1%).

[0084] 1 H NMR (400 MHz, CDCl3) δ 7.92 (dd, J = 7.8, 1.3 Hz, 1H), 7.82 (dd, J =7.7, 0.8 Hz, 1H), 7.77 (dd, J = 7.5, 1.1 Hz, 2H), 7.63 (m, 1H), 7.62 – 7.59 (m,1H), 7.51 (td, J = 7.6, 1.3 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 3.05 (t, J = 7.4 Hz,2H), 1.82 – 1.72 (m, 2H), 1.37 – 1.21 (m, 10H), 0.88 (t, J = 7.2 Hz, 3H);13 C NMR (100 MHz, CDCl3) δ 201.2, 172.6, 157.5, 156.0, 132.0, 130.4, 130.3, 130.2,130.1, 129.3, 128.4, 124.7, 123.8, 115.8, 106.2, 39.5, 32.0, 29.6, 29.6,29.3, 24.7, 22.8, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 24 H 27 O4:378.19039;Found: 379.19089. Example 3 Preparation of Compound 3

[0085] Compound 3 (40 mg yellow solid, 40% yield) was prepared from compound 48 (104 mg, 0.29 mmol) and 2-alkynylaniline (34 mg, 0.29 mmol) using the same synthetic method as compound 1.

[0086] 1 H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 7.7 Hz, 1H), 7.78 (s, 1H), 7.69 (dd, J = 17.0, 8.0 Hz, 2H), 7.32 (t, J = 7.9 Hz, 1H), 7.19 (t, J = 7.7 Hz,1H), 6.84 (t, J = 7.6 Hz, 1H), 6.78 (d, J = 8.2 Hz, 1H), 4.57 (br., 2H), 3.06(t, J = 7.5 Hz, 2H), 1.85 – 1.77 (m, 2H), 1.42 (m, 2H), 1.40 – 1.25 (m, 8H),0.90 (t, J = 6.6 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 201.2, 158.4, 155.0,144.6, 130.4, 129.6, 128.8, 128.7, 124.8, 123.2, 118.6, 117.1, 115.4, 114.9,104.4, 39.4, 32.0, 29.6, 29.6, 29.3, 24.7, 22.8,14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 23 H 28 O2N:350.21146; Found: 350.21164. Example 4: Preparation of Compound 4

[0087] Compound 4 (54 mg yellow solid, 24% yield) was prepared from compound 48 (200 mg, 0.56 mmol) and compound 29 (98 mg, 0.56 mmol) using the same synthetic method as compound 1.

[0088] 1 H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 7.6 Hz, 1H), 7.71 – 7.60 (m, 3H), 7.56 (d, J = 1.9 Hz, 1H), 7.36 (dd, J = 8.0, 1.9 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 3.82 (s, 3H), 3.05 (t, J = 7.4 Hz, 2H), 2.42 (s, 3H), 1.79 (p, J = 7.4 Hz, 2H),1.40 – 1.19 (m, 10H), 0.88 (t, J = 8.4 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.0,169.4, 157.7, 155.8, 139.6, 132.0, 131.0, 130.2, 130.0, 129.4, 128.6, 126.6,124. 7, 123.6, 115.5, 105.4, 52.5, 39.5, 32.0, 29.6, 29.6, 29.3, 24.7, 22.8,21.3, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 26 H 31 O4:407.22169; Found: 407.22226. Example 5: Preparation of Compound 5

[0089] Compound 5 (25 mg yellow solid, 96% yield) was prepared from compound 4 (30 mg, 0.08 mmol) using the same synthetic method as compound 2.

[0090] 1 H NMR (400 MHz, CDCl3) 7.76 (d, J = 7.7 Hz, 1H), 7.70 (s, 1H), 7.68 (s,1H), 7.63 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 8.2 Hz, 1H), 7.38 (d, J = 7.9 Hz, 1H), 7.23 (t, J = 7.9 Hz, 1H), 3.01 (t, J = 7.4 Hz, 2H), 2.40 (s, 3H), 1.74 (m, 2H), 1.36 – 1.19 (m, 10H), 0.88 (t, J = 6.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.3,157.7, 155.9, 139.6, 132.6, 131.0, 130.1, 129.9, 128.5, 127.4, 124.6, 123.5,115.8, 105.7, 39.5, 32.0, 29.8, 29.6, 29.6, 29.3, 24.7, 22.8, 21.3, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 25 H 29 O4:393.20604; Found: 393.20636. Example 6 Preparation of Compound 6

[0091] Compound 6 (52 mg of yellow oil, 51% yield) was prepared from compound 48 (100 mg, 0.28 mmol) and compound 30 (37 mg, 0.28 mmol) using the same synthetic method as compound 1.

[0092] 1 H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 7.6 Hz, 1H), 7.77 (s, 1H), 7.67(d, J = 8.1 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.31 (t, J = 7.9 Hz, 1H), 7.01 (dd, J = 8.2, 2.1 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 4.44 (br., 2H), 3.06 (t, J = 7.4Hz, 2H), 2.31 (s, 3H), 1.79 (m, 2H), 1.37 – 1.24 (m, 10H), 0.89 (t, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 201.2, 158.6, 155.0, 142.2, 131.3, 129.5,128.9, 128.7, 127.8, 124.8, 123.1, 117.3, 115.3, 114.8, 104.3, 39.4, 32.0,29.6, 29.6, 29.3, 24.7, 22.8, 20.5, 14.2; HRMS(ESIMS)m / z(M+H) + calcd forC 24 H 30 O2N:364.22711; Found: 364.22748. Example 7 Preparation of Compound 7

[0093] Compound 7 (yellow oil, 68 mg, yield 36%) was prepared from compound 49 (173 mg, 0.52 mmol) and compound 28 (83 mg, 0.52 mmol) using the same synthetic method as compound 1.

[0094] 1 H NMR (500 MHz, CDCl3) δ 7.84 (d, J = 7.6 Hz, 1H), 7.81 – 7.72 (m, 3H), 7.65 (d, J = 8.1 Hz, 1H), 7.57 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.6 Hz, 1H), 7.35(t, J = 8.0 Hz, 1H), 3.82 (s, 3H), 3.06 (t, J = 7.4 Hz, 2H), 1.80 (p, J = 7.6 Hz,2H), 1.43 (m, 2H), 1.35 (m, 4H), 0.91 (t, J = 6.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 201.0, 169.2, 157.5, 155.9, 131.3, 131.2, 130.2, 129.6, 129.5,129.5, 129.2, 128.5, 124.7, 123.8, 115.6, 106.0, 52.6, 39.5, 31.8, 29.3,24.7, 22.7, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 23 H 25 O4: 365.17474; Found:365.17520. Example 8: Preparation of Compound 8

[0095] Following the synthetic method of compound 2, compound 8 (yellow oil 47 mg, yield 67%) was prepared from compound 7 (66 mg, 0.19 mmol).

[0096] 1 H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 7.8 Hz, 1H), 7.81 (d, J = 7.6 Hz, 1H), 7.77 (d, J = 6.6 Hz, 2H), 7.66 – 7.57 (m, 2H), 7.50 (t, J = 7.6 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 3.04 (t, J = 7.4 Hz, 2H), 1.77 (p, J = 7.4 Hz, 2H), 1.47– 1.36 (m, 2H), 1.32 (m, 4H), 0.89 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3)δ 201.3, 172.8, 157.4, 156.0, 132.1, 130.4, 130.3, 130.2, 130.2, 130.1,129.3, 128.4, 124.8, 123.8, 115.9, 106.2, 39.5, 31.8, 29.2, 24.6, 22.7, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 22 H 23 O4: 351.15909; Found: 351.15826. Example 9: Preparation of Compound 9

[0097] Compound 9 (58 mg yellow solid, 44% yield) was prepared from compound 49 (137 mg, 0.41 mmol) and 2-alkynylaniline (48 mg, 0.41 mmol) using the same synthetic method as compound 1.

[0098] 1 H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 7.7 Hz, 1H), 7.78 (d, J = 1.0 Hz, 1H), 7.71 (dd, J = 7.9, 1.6 Hz, 1H), 7.68 (m, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.19(ddd, J = 8.4, 7.2, 1.5 Hz, 1H), 6.84 (td, J = 7.5, 1.2 Hz, 1H), 6.79 (dd, J = 8.1,1.2 Hz, 1H), 4.57 (br., 2H), 3.07 (t, J = 7.4 Hz, 2H), 1.80 (p, J = 7.3 Hz, 2H),1.45 – 1.40 (m, 2H), 1.35 (dq, J = 7.2, 3.6 Hz, 4H), 0.91 (t, J = 6.8 Hz, 3H); 13CNMR (126 MHz, CDCl3) δ 201.2, 158.4, 155.0, 144.6, 130.4, 129.6, 128.8,128.7, 124.8, 123.2, 118.6, 117.1, 115.4, 114.9, 104.4, 39.4, 31.9, 29.3,24.6, 22.7, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 21 H 24 O2N:322.18016; Found:322.17999. Example 10: Preparation of Compound 10

[0099] Compound 10 (51 mg of yellow oil, 24% yield) was prepared from compound 49 (188 mg, 0.57 mmol) and compound 29 (99 mg, 0.57 mmol) using the same synthetic method as compound 1.

[0100] 1 H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 7.6 Hz, 1H), 7.68 (t, J = 4.0 Hz, 2H), 7.64 (d, J = 8.1 Hz, 1H), 7.57 (s, 1H), 7.38 (d, J = 8.0 Hz, 1H), 7.33 (t, J =7.9 Hz, 1H), 3.82 (s, 3H), 3.06 (t, J = 7.4 Hz, 2H), 2.44 (s, 3H), 1.79 (p, J =7.5 Hz, 2H), 1.43 (m, 2H), 1.34 (m, 4H), 0.90 (t, J = 5.6 Hz, 3H); 13C NMR (126MHz, CDCl3) δ 201.1, 169.4, 157.7, 155.8, 139.6, 132.0, 131.1, 130.2, 130.1,129.4, 128.6, 126.7, 124.7, 123.6, 115.5, 105.4, 52.6, 39.5, 31.9, 29.3,24.7, 22.7, 21.3, 14.2; HRMS(ESIMS)m / z(M+H) + calcd for C 24 H 27 O4: 379.19039;Found: 379.18991. Example 11 Preparation of Compound 11

[0101] Following the synthetic method of compound 2, compound 11 (colorless oil, 43 mg, yield 91%) was prepared from compound 10 (51 mg, 0.13 mmol).

[0102] 1 H NMR (500 MHz, CDCl3) δ 7.81 (d, J = 7.6 Hz, 1H), 7.75 – 7.69 (m, 2H), 7.66 (d, J = 7.8 Hz, 1H), 7.61 (d, J = 8.1 Hz, 1H), 7.42 (dd, J = 7.9, 1.9 Hz, 1H), 7.29 (t, J = 7.9 Hz, 1H), 3.04 (t, J = 7.4 Hz, 2H), 2.45 (s, 3H), 1.77 (p, J = 7.5Hz, 2H), 1.44 – 1.29 (m, 5H), 1.26 (s, 1H), 0.89 (t, J = 5.6 Hz, 3H); 13C NMR(101 MHz, CDCl3) δ 201.2, 172.8, 157.7, 155.9, 139.7, 132.8, 131.0, 130.2,130.0, 129.8, 128.6, 127.6, 124.7, 123.6, 115.8, 105.8, 39.5, 31.9, 29.3,24.7, 22.7, 21.3, 14.2, HRMS(ESIMS)m / z(M+H) + calcd for C 23 H 24 O4:365.17474; Found:365.17542. Example 12 Preparation of Compound 12

[0103] Compound 12 (85 mg yellow solid, 56% yield) was prepared from compound 49 (150 mg, 0.45 mmol) and compound 30 (59 mg, 0.45 mmol) using the same synthetic method as compound 1.

[0104] 1 H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 7.7, 0.8 Hz, 1H), 7.77 (d, J = 0.9Hz, 1H), 7.68 (m, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.02(dd, J = 8.2, 2.1 Hz, 1H), 6.72 (d, J = 8.1 Hz, 1H), 4.46 (br., 2H), 3.07 (t, J =7.4 Hz, 2H), 2.31 (s, 3H), 1.80 (p, J = 7.4 Hz, 2H), 1.43 (m, 2H), 1.35 (m,4H), 0.91 (t, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.1, 158.5, 155.0,142.2, 131.3, 129.5, 128.8, 128.7, 127.7, 124.7, 123.0, 117.3, 115.3, 114.8,104.2, 39.4, 31.9, 29.2, 24.6, 22.7, 20.5, 14.2.; HRMS(ESIMS)m / z(M+H) + calcdfor C 22 H 26 NO2: 336.19581; Found: 336.19669. Example 13 Preparation of Compound 13

[0105] Compound 13 (41 mg yellow solid, 48% yield) was prepared from compound 51 (100 mg, 0.34 mmol) and compound 30 (45 mg, 0.34 mmol) using the same synthetic method as compound 1.

[0106] 1 H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 7.7 Hz, 1H), 7.77 (d, J = 1.0 Hz, 1H), 7.68 (dd, J = 8.2, 1.0 Hz, 1H), 7.54 (d, J = 2.1 Hz, 1H), 7.32 (t, J = 7.9 Hz, 1H), 7.02 (dd, J = 8.2, 2.1 Hz, 1H), 6.71 (d, J = 8.2 Hz, 1H), 4.44 (br., 2H), 3.06 (t, J = 7.3 Hz, 2H), 2.31 (s, 3H), 1.84 (h, J = 7.4 Hz, 2H), 1.05 (t, J = 7.4Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 201.1, 158.6, 155.1, 142.2, 131.4, 129.6,128.9, 128.7, 127.8, 124.8, 123.1, 117.3, 115.4, 114.8, 104.3, 41.4, 20.6,18.1, 14.1; HRMS (ESIMS)m / z(M+H) + calcd for C 19 H 20 O2N: 294.14886; Found: 294.14841. Example 14 Preparation of Compound 14

[0107] Following the synthetic method of compound 1, compound 14 (45 mg yellow solid, 49% yield) was prepared from compound 51 (90 mg, 0.31 mmol) and 2-alkynylaniline (36 mg, 0.31 mmol)

[0108] 1 H NMR (500 MHz, CDCl3) δ 7.83 (d, J = 7.5 Hz, 1H), 7.77 (s, 1H), 7.69(dd, J = 13.8, 7.8 Hz, 2H), 7.32 (t, J = 7.7 Hz, 1H), 7.19 (t, J = 7.4 Hz, 1H), 6.87 – 6.76 (m, 2H), 4.54 (br., 2H), 3.05 (t, J = 7.1 Hz, 2H), 1.88 – 1.80 (m,2H), 1.05 (t, J = 7.2 Hz, 3H); 13 C NMR (126 MHz, CDCl3) δ 201.0, 158.4, 155.1,144.6, 130.5, 129.6, 128.9, 128.7, 124.8, 123.2, 118.6, 117.1, 115.4, 114.9,104.4, 41.4, 18.1, 14.1. HRMS (ESIMS)m / z(M+H) + calcd for C 18 H18 NO2:280.13321;Found:280.13400. Example 15 Preparation of Compound 15 Step A: Dissolve p-methoxyphenol (2 g, 16 mmol) in 20 mL of anhydrous dichloromethane in a 100 mL single-necked flask. Cool the reaction mixture to 0 °C, then add N,N-diisopropylethylamine (5.28 mL, 32 mmol) and chloromethyl methyl ether (1.70 mL, 20 mmol) dropwise. Raise the reaction mixture to room temperature and stir for 1 h. Monitor the reaction progress by TLC. Quench the reaction mixture with distilled water. Separate the mixture, wash the organic phase with saturated sodium bicarbonate solution, and dry with anhydrous sodium sulfate. Filter, remove the solvent under reduced pressure, and purify by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to give compound 52 (1.69 g of colorless oil, 63% yield).

[0109]

[0110] 1 H NMR (400 MHz, CDCl3) δ 6.98 (d, J = 9.1 Hz, 2H), 6.83 (d, J = 9.1Hz, 2H), 5.11 (s, 2H), 3.77 (s, 3H), 3.48 (s, 3H). Step B: Compound 52 (1.64 g, 9.8 mmol) was dissolved in 25 mL of anhydrous diethyl ether and placed in a 50 mL three-necked flask. Ar was used for purging three times. The reaction solution temperature was lowered to 0 °C, and n-butyllithium (1.6 M, 7.35 mL, 12 mmol) was added dropwise. The reaction was brought to room temperature and stirred for 3.5 h. The solution color changed from clear and transparent to milky white, then to pale yellow. Iodine (3.22 g, 13 mmol) in anhydrous diethyl ether was added, and the reaction was stirred at room temperature for 0.5 h. The reaction was monitored by TLC until the starting material was completely reacted. The reaction was terminated by adding ammonia-ammonium chloride buffer (pH=8). The mixture was extracted three times with methyl tert-butyl ether, and the organic phases were combined and dried over anhydrous sodium sulfate. After filtration, the solvent was removed by vacuum distillation, and the mixture was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to give compound 53 (2.612 g of brown oil, 91% yield).

[0111]

[0112] 1 H NMR (400 MHz, CDCl3) δ 7.32 (d, J = 3.0 Hz, 1H), 7.00 (d, J= 9.0 Hz, 1H), 6.84 (dd, J = 9.0, 3.0 Hz, 1H), 5.15 (s, 2H), 3.75 (s, 3H), 3.52 (s, 3H). Step C: Compound 53 (2.46 g, 8 mol) was dissolved in 25 mL of methanol and placed in a 100 mL single-necked flask. 10% hydrochloric acid (3.2 N, 4.1 mL) was added, and the mixture was heated under reflux for 20 min. The reaction mixture was monitored by TLC until the starting material was completely reacted. The reaction solution was cooled to room temperature, and methanol was removed by vacuum distillation. A small amount of distilled water was added to the system, and the mixture was extracted with ethyl acetate. The organic phases were combined and dried over anhydrous sodium sulfate. The mixture was filtered, and the solvent was removed by vacuum distillation. The solution was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 10:1) to give compound 54 (1.783% light red oil, 77% yield).

[0113]

[0114] 1 H NMR (400 MHz, CDCl3) δ 6.94 (dd, J = 8.8, 0.5 Hz, 1H), 6.86 (dd, J= 8.8, 3.0 Hz, 1H), 6.83 (d, J = 3.2 Hz, 1H), 5.79 (br., 1H), 3.79 (s, 3H); 13 CNMR (100 MHz, CDCl3) δ 154.3, 146.7, 125.2, 117.9, 116.0, 115.6, 55.9. Step D: Following the synthesis method of compound 25, compound 55 (1.39 g of brown oil, 99% yield) was prepared from compound 54 (1.66 g, 6.6 mmol).

[0115]

[0116] 1 H NMR (400 MHz, CDCl3) δ 7.25 (m, 3H), 5.92 (br., 1H), 4.15 (s, 3H), 0.28 (s, 9H); 13 C NMR (100 MHz, CDCl3) δ 153.0, 151.6, 118.1, 115.6, 115.2,109.5, 102.3, 99.3, 55.9, 0.1; HRMS (ESI) m / z (M+H) +calcd for C 12 H 17 O2Si:221.09923; Found:221.09895. Step E: Following the synthesis method of compound 38, compound 56 (yellow oil 2.04 g, yield 99%) was prepared from compound 55 (1.39 g, 6.3 mmol).

[0117]

[0118] 1 H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 9.0 Hz, 1H), 6.94 (d, J = 3.1 Hz, 1H), 6.80 (dd, J = 9.0, 3.1 Hz, 1H), 5.21 (s, 2H), 3.85 – 3.78 (m, 2H), 3.76(s, 3H), 1.01 – 0.90 (m, 2H), 0.25 (s, 9H), 0.02 (s, 9H); 13 C NMR (100 MHz, Chloroform-d) δ 154.3, 153.8, 117.9, 116.5, 115.5, 114.4, 113.8, 94.4, 66.4,55.9, 18.2, 0.2, -1.2; HRMS (ESI) m / z (M+H) + calcd for C 18 H 31 O3Si2:351.18062;Found:351.17798. Step F: Compound 56 (2.045 g, 6 mmol) was dissolved in 20 mL of methanol and placed in a 50 mL single-necked flask. Potassium carbonate (84 mg, 0.6 mmol) was added with stirring, and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was monitored by TLC until the starting material was completely reacted. The solvent was removed under reduced pressure, and the mixture was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 150:1) to give compound 57 (1.5 g of yellow oil, 90% yield).

[0119]

[0120] 1H NMR (400 MHz, CDCl3) δ 7.08 (d, J = 9.1 Hz, 1H), 6.98 (d, J = 3.1Hz, 1H), 6.85 (dd, J = 9.1, 3.1 Hz, 1H), 5.23 (s, 2H), 3.85 – 3.78 (m, 2H), 3.75 (s, 3H), 3.26 (s, 1H), 0.98 – 0.91 (m, 2H), -0.001 (s, 9H); 13 C NMR (100MHz, CDCl3) δ 154.2, 153.0, 118.3, 117.3, 116.6, 113.4, 94.4, 81.0, 80.2,66.5, 55.8, 18.2, -1.3. Step G: Compound 58 (yellow oil 87 mg, yield 47%) was prepared from compound 48 (130 mg, 0.36 mmol) and compound 57 (100 mg, 0.39 mmol) using the same method as compound 1.

[0121]

[0122] 1 H NMR (500 MHz, CDCl3) δ 8.12 (s, 1H), 7.85 (d, J = 7.6 Hz, 1H), 7.72(d, J = 8.1 Hz, 1H), 7.63 (d, J = 3.2 Hz, 1H), 7.36 (t, J = 7.9 Hz, 1H), 7.28(d, J = 8.8 Hz, 1H), 6.92 (dd, J = 9.0, 3.1 Hz, 1H), 5.41 (s, 2H), 3.91 (s,3H), 3.90 – 3.84 (m, 2H), 3.10 (t, J = 7.5 Hz, 2H), 1.84 (p, J = 7.5 Hz, 2H),1.50 – 1.43 (m, 2H), 1.43 – 1.25 (m, 8H), 1.02 (t, J = 6.4 Hz, 2H), 0.92 (t, J =6.7 Hz, 3H), 0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 201.0, 154.8, 154.7,154.5, 149.4, 130.1, 129.3, 124.6, 123.5, 120.6, 116.9, 115.8, 115.3, 112.1,107.9, 93.7, 66.6, 56.0, 39.7, 32.0, 29.6, 29.3, 24.8, 22.8, 18.2, 14.2, -1.3; HRMS (ESI) m / z (M+H) + calcd for C 30 H 43 O5Si: 511.28743; Found: 511.28989 Step H: Following the synthetic method of compound 48, compound 59 (20 mg of pale yellow solid, 52% yield) was prepared from compound 58 (50 mg, 0.1 mmol).

[0123]

[0124] 1 H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 0.9 Hz, 1H), 7.86 (dd, J = 7.8,0.9 Hz, 1H), 7.70 (dt, J = 8.2, 0.9 Hz, 1H), 7.36 (t, J = 7.8 Hz, 1H), 7.31(d, J = 3.0 Hz, 1H), 6.96 – 6.92 (m, 2H), 6.87 (dd, J = 8.2, 3.0 Hz, 1H), 3.84 (s, 3H), 3.08 (t, J = 7.6 Hz, 2H), 1.87 – 1.73 (m, 2H), 1.47 – 1.22 (m,10H), 0.88 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 201.5, 156.7, 154.8,153.7, 148.2, 129.9, 128.8, 125.2, 123.7, 118.5, 117.9, 116.1, 115.5, 111.0,105.5, 56.1, 39.5, 32.0, 29.6, 29.6, 29.3, 24.7, 22.8, 14.2; HRMS (ESI) m / z (M+H) + calcd for C 24 H 29 O4:381.20604; Found: 381.20615. Step I: Compound 59 and N,N-dimethylformyl chloride were dissolved in ultra-dry acetonitrile, K2CO3 was added under stirring, and the mixture was refluxed for 1 h. The reaction was confirmed by TLC to be complete. The solvent was removed by vacuum distillation, and saturated sodium carbonate solution was added. The mixture was extracted with ethyl acetate and purified by silica gel column chromatography (petroleum ether: dichloromethane = 1:1) to obtain compound 15 (56 mg of white solid, yield 96%).

[0125]

[0126] 1 H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 0.9 Hz, 1H), 7.81 (dd, J = 7.7, 0.9Hz, 1H), 7.67 (dd, J = 8.1, 0.9 Hz, 1H), 7.54 (d, J = 3.0 Hz, 1H), 7.34 (t, J = 7.9Hz, 1H), 7.15 (d, J = 8.9 Hz, 1H), 6.93 (dd, J = 8.9, 3.1 Hz, 1H), 3.89 (s, 3H), 3.39 (s, 3H), 3.06 (s, 3H), 3.03 (t, J = 7.5 Hz, 2H), 1.84 – 1.72 (m, 2H), 1.41– 1.25 (m, 10H), 0.89 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 200.9,157.2, 155.0, 154.7, 154.1, 142.3, 129.9, 128.8, 125.1, 124.8, 124.0, 123.8,115.8, 115.5, 111.9, 107.0, 55.9, 39.5, 37.0, 36.7, 31.9, 29.6, 29.3, 25.0,22.8, 14.2; HRMS (ESIMS) m / z (M+H) + calcd for C 27 H 34 O5N:452.24315; Found:452.24365. Example 16 Preparation of Compound 16

[0127] Compound 16 (50 mg white solid, 89% yield) was prepared from compound 59 (50 mg, 0.13 mmol) using the same synthetic method as compound 15.

[0128] 1 H NMR (500 MHz, CDCl3) δ 7.86 (s, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.66(d, J = 8.0 Hz, 1H), 7.55 – 7.49 (m, 1H), 7.33 (t, J = 7.9 Hz, 1H), 7.14 (t, J =9.3 Hz, 1H), 6.93 (dd, J = 8.8, 3.1 Hz, 1H), 3.88 (s, 3H), 3.73 (d, J = 7.3 Hz,1H), 3.43 (m, 1H), 3.36 (s, 2H), 3.03 (t, J = 5.6 Hz, 3H), 1.82 – 1.71 (m, 2H), 1.37 – 1.21 (m, 11H), 1.18 (t, J = 6.4 Hz, 2H), 0.88 (t, J = 6.9 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 200.8, 157.2, 155.0, 154.2, 142.4, 130.0, 128.9, 125.1,124.7, 124.1, 123.8, 115.9, 115.4, 112.2, 112.0, 106.8, 55.9, 44.4, 44.1,39.4, 34.1, 32.0, 29.6, 29.3, 24.9, 22.8, 14.2, 12.5; HRMS (ESIMS) m / z (M+H) + calcd for C 28 H 36 O5N:466.25880; Found: 466.25961. Example 17 Preparation of Compound 17

[0129] Compound 17 (56 mg pale yellow solid, 90% yield) was prepared from compound 59 (50 mg, 0.13 mmol) using the same synthetic method as compound 15.

[0130] 1 H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 0.9 Hz, 1H), 7.80 (dd, J = 7.7, 0.8Hz, 1H), 7.66 (dt, J = 8.1, 0.9 Hz, 1H), 7.51 (d, J = 3.1 Hz, 1H), 7.33 (t, J = 7.9Hz, 1H), 7.12 (d, J = 8.9 Hz, 1H), 6.93 (dd, J = 8.9, 3.1 Hz, 1H), 3.88 (s, 3H), 3.71 (q, J = 7.1 Hz, 2H), 3.42 (q, J = 7.1 Hz, 2H), 3.03 (t, J = 7.4 Hz, 2H), 1.82– 1.71 (m, 2H), 1.45 – 1.24 (m, 13H), 1.19 (t, J=7.1 Hz, 3H), 0.89 (t, J =7.2 Hz, 3H); 13 C NMR (100MHz, CDCl3) δ 200.7, 157.2, 155.1, 154.5, 154.1,142.4, 130.0, 128.8, 125.0, 124.7, 124.3, 123.8, 116.0, 115.5, 112.2, 106.7,55.9, 42.2, 41.9, 39.4, 32.0, 29.6, 29.6, 29.3, 24.9, 22.8, 14.3, 14.2, 13.3;HRMS (ESIMS) m / z (M+H) + calcd for C 29 H 38 O5N:480.27445; Found: 480.27679. Example 18 Preparation of Compound 18

[0131] Compound 18 (58 mg white solid, 94% yield) was prepared from compound 59 (50 mg, 0.13 mmol) using the same synthetic method as compound 15.

[0132] 1 H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 0.9 Hz, 1H), 7.80 (dd, J = 7.8, 0.8Hz, 1H), 7.66 (dt, J = 8.2, 0.9 Hz, 1H), 7.54 (d, J = 3.1 Hz, 1H), 7.34 (t, J = 7.9Hz, 1H), 7.18 (d, J = 8.9 Hz, 1H), 6.93 (dd, J = 8.9, 3.0 Hz, 1H), 3.89 (s, 3H), 3.88 – 3.85 (m, 2H), 3.51 (t, J = 6.8 Hz, 2H), 3.03 (t, J= 7.4 Hz, 2H), 2.16 –2.08 (m, 2H), 2.02 – 1.97 (m, 2H), 1.77 (m, 2H), 1.36 – 1.24 (m, 10H), 0.89(t, J = 7.2 Hz, 3H); 13 C NMR (100 MHz, CDCl3) δ 200.7, 157.2, 155.0, 154.2,152.9, 142.3, 130.0, 128.9, 125.2, 124.7, 124.0, 123.8, 115.8, 115.4, 111.9,107.1, 55.9, 46.9, 46.7, 39.3, 32.0, 29.6, 29.6, 29.3, 26.1, 25.1, 24.8,22.8, 14.2; HRMS (ESIMS) m / z (M+H) + calcd for C 29 H 36 O5N:478.25880; Found:478.25952. Example 19 Preparation of Compound 19

[0133] Compound 19 (60 mg white solid, 94% yield) was prepared from compound 59 (50 mg, 0.13 mmol) using the same synthetic method as compound 15.

[0134] 1 H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 2.5 Hz, 1H), 7.82 (dd, J = 7.7, 2.5Hz, 1H), 7.68 (dd, J = 8.2, 2.5 Hz, 1H), 7.54 (d, J = 2.9 Hz, 1H), 7.35 (t, J = 7.9Hz, 1H), 7.15 (dd, J = 9.0, 2.4 Hz, 1H), 6.94 (dd, J = 8.8, 3.0 Hz, 1H), 3.95 (s,4H), 3.89 (s, 3H), 3.81 (d, J= 8.9 Hz, 2H), 3.60 (s, 2H), 3.04 (td, J = 7.4, 2.5Hz, 2H), 1.78 (m, 2H), 1.40 – 1.20 (m, 10H), 0.89 (t, J = 7.2 Hz, 3H); 13 C NMR(100MHz, CDCl3) δ 200.7, 157.4, 155.0, 154.0, 153.5, 141.9, 130.0, 128.8,125.0, 124.8, 124.1, 123.9, 115.8, 115.5, 112.1, 107.0, 66.7, 55.9, 45.1,44.4, 39.2, 32.0, 29.6, 29.3, 24.8, 22.8, 14.2; HRMS (ESIMS) m / z(M+H) + calcdfor C 29 H 36 O6N:494.25371; Found: 494.25421. Example 20 Preparation of Compound 20

[0135] Compound 9 (87 mg, 0.27 mmol) was dissolved in 3 mL of anhydrous dichloromethane in a 25 mL single-necked flask. The reaction solution was cooled to 0 °C, and ultradry pyridine (22 μl, 0.27 mmol) and ethyl chloroformate (26 μl, 0.27 mmol) were added with stirring. After the addition was complete, the mixture was stirred at 0 °C for 5 min, and the reaction was monitored by TLC until the starting material was completely reacted. The reaction solution was quenched with distilled water, separated, and the aqueous phase was extracted with dichloromethane and dried over anhydrous sodium sulfate. The solution was filtered, the solvent was removed under reduced pressure, and the solution was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 1:1) to give compound 20 (100 mg of yellow solid, 87% yield).

[0136] 1 H NMR (400 MHz, CDCl3) δ 8.17 (d, J = 8.4 Hz, 1H), 8.09 (br., 1H), 7.88(dd, J = 7.7, 0.8 Hz, 1H), 7.83 (d, J = 0.9 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.48 –7.36 (m, 2H), 7.20 (td,J = 7.6, 1.2 Hz, 1H), 4.45 (t, J = 6.4 Hz, 2H), 3.76 (t, J = 6.0 Hz, 2H), 3.08 (t, J = 7.4 Hz, 2H), 1.80 (p, J = 7.2 Hz, 2H), 1.49 – 1.39(m, 2H), 1.43 – 1.32 (m, 4H), 0.91 (t, J = 8.8 Hz, 3H); 13 C NMR (126 MHz, CDCl3)δ 200.9, 156.8, 155.4, 153.2, 135.1, 130.4, 130.0, 129.0, 128.0, 125.1,124.1, 124.0, 121.4, 119.7, 115.6, 106.3, 64.9, 41.9, 39.4, 31.8, 29.2, 24.6,22.6, 14.2; HRMS (ESIMS) m / z(M+H) + calcd for C 24 H 27 ClNO4:428.16231; Found:428.16260. Example 21 Preparation of Compound 21

[0137] Following the synthetic method of compound 20, compound 21 (51 mg yellow solid, 98% yield) was prepared from compound 9 (40 mg, 0.12 mmol) and ultradry pyridine (10 μl, 0.12 mmol) and chloromethyl isobutyl ester (15 μl, 0.12 mmol).

[0138] 1 H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 8.4 Hz, 1H), 7.86 (d, J = 7.7 Hz,2H), 7.80 (s, 1H), 7.72 (d, J = 8.1 Hz, 1H), 7.56 (s, 1H), 7.38 (t, J = 7.9 Hz, 1H), 7.22 (dd, J= 8.4, 2.1 Hz, 1H), 3.97 (d, J = 6.7 Hz, 2H), 3.07 (t, J = 7.4 Hz, 2H), 2.37 (s, 3H), 2.08 – 1.93 (m, 1H), 1.80 (p, J = 7.4 Hz, 2H), 1.47 – 1.39(m, 2H), 1.35 (m, 4H), 0.98 (d, J = 6.7 Hz, 6H), 0.91 (t, J = 7.2 Hz, 3H); 13 C NMR (126 MHz, CDCl3) δ 201.0, 157.4, 155.4, 154.2, 133.4, 133.2, 131.2, 130.1,129.3, 128.2, 125.0, 123.9, 122.3, 121.6, 115.6, 106.0, 71.6, 39.4, 31.9,29.3, 28.1, 24.6, 22.7, 20.8, 19.2, 14.2; HRMS (ESIMS) m / z(M+H) + calcd forC 27 H 34 NO4:436.24824; Found:436.24866. Example 22 Preparation of Compound 22

[0139] Following the synthetic method of compound 20, compound 22 (114 mg yellow solid, 84% yield) was prepared from compound 9 (100 mg, 0.34 mmol) and ultradry pyridine (27 μl, 0.34 mmol) and chloromethyl chloroethyl ester (33 μl, 0.34 mmol).

[0140] 1 H NMR (400 MHz, CDCl3) δ7.99 (m, 2H), 7.87 (dd, J = 7.7, 0.9 Hz, 1H), 7.81 (d, J = 0.9 Hz, 1H), 7.74 (dt, J = 8.2, 0.9 Hz, 1H), 7.58 (d, J = 2.7 Hz, 1H), 7.39 (t,J = 8 Hz, 1H), 7.23 (dd, J = 8.5, 2.1 Hz, 1H), 4.44 (t, J = 6.0 Hz, 2H), 3.75 (t, J = 5.6 Hz, 2H), 3.06 (t, J = 7.3 Hz, 2H), 2.38 (s, 3H), 1.84 (h, J = 7.4Hz, 2H), 1.05 (t, J = 7.4 Hz, 3H); 13 C NMR (126 MHz, CDCl3) δ 200.9, 157.1,155.5, 153.4, 133.9, 132.6, 131.2, 130.1, 129.4, 128.1, 125.1, 124.0, 121.8,120.2, 115.7, 106.2, 65.0, 42.0, 41.4, 20.9, 18.1, 14.1; HRMS (ESIMS) m / z(M+H) + calcd for C 22 H 23 NO4Cl : 400.13101; Found:400.13190. Example 23 Preparation of Compound 23 Step A: Following the synthesis method of compound 1, compound 60 (86 mg of yellow oil, 40% yield) was prepared from compound 50 (150 mg, 0.43 mmol) and compound 57 (120 mg, 0.43 mmol).

[0141]

[0142] 1 H NMR (400 MHz, CDCl3) δ 7.57 (d, J = 3.1 Hz, 1H), 7.45 (d, J = 8.6 Hz, 1H), 7.33 (d, J = 1.0 Hz, 1H), 7.20 (d, J = 9.1 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.87 (dd, J= 9.0, 3.2 Hz, 1H), 5.30 (s, 2H), 3.87 (s, 3H), 3.79 (t, J = 8.4 Hz, 2H), 2.94 (t, J = 7.6 Hz, 2H), 2.45 (s, 3H), 1.37 – 1.28 (m, 2H), 1.26 (m, 6H), 0.96 (t, J = 8 Hz, 2H), 0.88 (t, J = 7.2 Hz, 3H), -0.02 (s, 9H); 13 C NMR (151 MHz, CDCl3) δ 207.1, 154.6, 152.5, 148.9, 133.3, 130.0, 129.6, 127.5, 127.4,120.5, 116.7, 115.6, 112.4, 111.8, 105.6, 93.7, 66.6, 56.0, 44.4, 31.8, 27.4,24.5, 22.7, 20.0, 18.2, 14.2, -1.3; HRMS(ESIMS)m / z(M+H) + calcd for C 29 H 41 O5Si:497.27178; Found:497.27075. Step B: Following the synthetic method of compound 48, compound 23 (brown oil 51 mg, yield 87%) was prepared from compound 60 (82 mg, 0.16 mmol)

[0143]

[0144] 1 H NMR (400 MHz, CDCl3) δ 7.44 (dd, J = 8.3, 1.0 Hz, 1H), 7.27 (d, J = 3.0Hz, 1H), 7.16 (d, J = 1.0 Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.89 (d, J = 8.8 Hz, 1H), 6.83 (dd, J= 8.9, 3.0 Hz, 1H), 6.75 (br.s, 1H), 3.83 (s, 3H), 2.93 (t, J =7.6 Hz, 2H), 2.46 (s, 3H), 1.76 (p, J = 7.5 Hz, 2H), 1.43 – 1.35 (m, 2H), 1.36 – 1.21 (m, 4H), 0.88 (t, J = 6.8 Hz, 3H); 13 C NMR (101 MHz, CDCl3) δ 207.6,154.9, 153.6, 152.6, 147.8, 133.24, 123.0, 127.5, 126.9, 118.2, 117.0, 116.5,112.5, 111.2, 103.5, 56.0, 44.4, 31.8, 29.2, 24.5, 22.6, 20.1, 14.1; HRMS(ESIMS)m / z(M+H) + calcd for C 23 H 27 O4: 367.19039; Found:367.19061. Example 24 Evaluation of the inhibitory effect of compounds 1-23 on hCES2A Using fluorescein diacetate (FD) as a substrate, the inhibitory activity of a series of compounds against hCES2A enzyme was determined, and the IC50 values ​​of each compound were obtained. 50 value: a. The total volume of the incubation system is 200 μL, which contains phosphate buffer at pH 7.4, hCES2A at a final concentration of 1 μg / mL, and fluorescent substrate FD at a final concentration of 8 μM. b. First, add hCES2A and the test compound into a 96-well plate and incubate at 37°C for 3 min. Then, add 2 µl FD (final concentration of 8 μM) to start the reaction. c. The generation of fluorescein, a hydrolysis product of FD, was continuously detected using a multifunctional microplate reader (0-30 min). fluorescein detection conditions: excitation wavelength 480 nm, emission wavelength 525 nm; d. Plot the inhibitor concentration on the x-axis and residual enzyme activity on the y-axis, and use software to calculate the IC50 of each compound inhibiting hCES2A. 50 Value. The formula for calculating residual enzyme activity is: Residual enzyme activity (%) = (F0 - F1) / F0 × 100% Where F0 is the fluorescence intensity value measured in the pre-incubation solution without the addition of inhibitors, and F1 is the fluorescence intensity value of the product measured in the pre-incubation solution with the addition of a specific concentration of inhibitors.

[0145] Table 1. Inhibition IC50 of 2-phenyl-4-acylbenzofuran compounds on hCES2A 50 .

Claims

1. A compound as shown in general formula I, or a pharmaceutically acceptable salt thereof: in: R1 is independently selected from C1-16 straight-chain or branched alkyl groups; R2 is independently selected from hydrogen, C1-10 alkyl, and C1-10 alkoxy; R3 is selected independently. 、 COOR7 ; R4 is independently selected from hydrogen, C1-10 alkyl, and C1-10 alkoxy. R5 and R6 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , , , ; R7 is independently selected from hydrogen and C1-10 alkyl groups; R8 is independently selected from hydrogen, C1-10 alkyl, and C1-10 haloalkyl; Halogens are represented by fluorine, chlorine, bromine, and iodine.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that, R1 is independently selected from C1-14 straight-chain or branched alkyl groups; R2 is independently selected from hydrogen, C1-8 alkyl, and C1-8 alkoxy. R3 Independent Selection COOR7 ; R4 is independently selected from hydrogen, C1-8 alkyl, and C1-8 alkoxy. R5 and R6 are independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , , , ; R7 is independently selected from hydrogen and C1-8 alkyl groups; R8 is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl; Halogens are represented by fluorine, chlorine, bromine, and iodine.

3. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, characterized in that: R1 is independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, tert-pentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, n-octyl, 2-methylheptyl, 3-methylheptyl, 4-methylheptyl, 2,2-dimethylhexyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,3,4-trimethylbutyl, n-nonyl, 2-methyloctyl, 3- Methyl octyl, 4-methyl octyl, 2,2-dimethyl heptyl, 2,3,4-trimethylpentyl, 2,3,5-trimethylpentyl, n-decyl, 2-methyl decyl, 3-methyl decyl, 4-methyl decyl, 5-methyl decyl, 2,2-dimethyl octyl, 2,3-dimethyl octyl, 2,4-dimethyl octyl, 2,5-dimethyl octyl, 2,6-dimethyl octyl, 2,7-dimethyl octyl, 2,3,4-trimethyl heptyl, 2,3,5-trimethyl heptyl, 2,3,6-trimethyl heptyl, 3,4,5-trimethyl heptyl, 3,4,6-trimethyl heptyl, 2,3,4,5-tetramethylhexyl, undecyl, dodecyl; R2 is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methylbutyl, pteropentyl, n-hexyl, 2-methylpentyl, 3-methylpentyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-methylbutoxy, pteropentyl, n-hexyloxy, 2-methylpentoxy, 3-methylpentoxy, 2,2-dimethylbutoxy, 2,3-dimethylbutoxy; R3 is independently selected from N,N-dimethylcarbamoyloxy, N-methyl-N-ethylcarbamoyloxy, N,N-diethylcarbamoyloxy, N-methyl-N-propylcarbamoyloxy, N-methyl-N-isopropylcarbamoyloxy, N-methyl-N-butylcarbamoyloxy, N-methyl-N-isobutylcarbamoyloxy, N-ethyl-N-propylcarbamoyloxy, N-ethyl-N-isopropylcarbamoyloxy, N-ethyl-N-butylcarbamoyloxy, N-ethyl-N-isobutylcarbamoyloxy, N-propyl-N-butylcarbamoyloxy, N-propyl-N-isobutylcarbamoyloxy N-Butyl-N-isobutylcarbamoyloxy, N,N-dibutylcarbamoyloxy, N,N-diisobutylcarbamoyloxy, 4-morpholinocarbamoyloxy, 1-pyrrolidinecarbamoyloxy, carboxyl, methyl formate, ethyl formate, propyl formate, isopropyl formate, butyl formate, isobutyl formate, methoxycarbamoylamino, ethoxycarbamoylamino, propoxycarbamoylamino, isopropoxycarbamoylamino, butoxycarbamoylamino, isobutoxycarbamoylamino, 2-chloroethoxycarbamoylamino, 2-chloropropoxycarbamoylamino, 3-chloropropoxycarbamoylamino, 2-chlorobutoxycarbamoylamino, 3-chlorobutoxycarbamoylamino, 4-chlorobutoxycarbamoylamino. R4 is independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, 2-methyl-butyl, ptert-pentyl, n-hexyl, 2-methyl-pentyl, 3-methyl-pentyl, 2,2-dimethyl-butyl, 2,3-dimethyl-butyl, methoxy, ethoxy, propoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, 2-methyl-butoxy, ptert-pentoxy, n-hexoxy, 2-methyl-pentoxy, 3-methyl-pentoxy, 2,2-dimethyl-butoxy, 2,3-dimethyl-butoxy; R5 and R6 are independently selected from methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl; or R5 and R6 are linked to form a ring: , , , , , , , , , , .

4. The following compounds or their pharmaceutically acceptable salts, characterized in that, The compound is selected from 。 5. A method for preparing the compound according to any one of claims 1-4, comprising the following steps: Fragment A preparation: Compound III was obtained by coupling commercially available compound II with trimethylsilylacetylene; fragment A was obtained by deprotecting compound III from TMS. i. Coupling reaction; ii. Deprotection; wherein R3 and R4 are defined as in any one of claims 1-3; Fragment B preparation: Compound V was obtained by iodination of commercially available compound IV. Compound V was obtained by oxidation of compound V. Compound VI was demethylated to obtain compound VII. Compound VII was protected by hydroxyl group to obtain compound VIII. Compound VIII was given an alkyl side chain by Grignard reaction to obtain compound IX. Compound IX was oxidized to obtain compound X. Compound X was deprotected to obtain fragment B. i. Iodination reaction; ii. Oxidation reaction; iii. Demethylation; iv. Adding a protecting group; v. Grignard reaction; vi. Oxidation reaction; vii. Deprotection; wherein R1 and R2 are defined as in any one of claims 1-3; R9 is methyl, ethyl, triethylsilyl, tert-butyldimethylsilyl, triphenylsilyl, (trimethylsilyl)ethoxymethyl; Synthesis of I: Compound I was obtained from fragments A and B via a Sonogashira coupling cyclization reaction; i. Sonogashira coupling cyclization reaction; wherein R1, R2, R3, R4 are defined as in any one of claims 1-3.

6. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises a compound of any one of claims 1-4 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

7. The pharmaceutical composition according to claim 6, characterized in that, The pharmaceutical composition includes tablets, capsules, pills, or injections.

8. The pharmaceutical composition according to claim 6, characterized in that, The pharmaceutical composition is selected from solutions, suspensions, emulsions, powders, controlled-release formulations, or sustained-release formulations.

9. Use of the compound of any one of claims 1-4 and its pharmaceutically acceptable salt in the preparation of a medicament having hCES2A inhibitory activity.

Citation Information

Patent Citations

  • Bysspectin a derivatives, methods of making and pharmaceutical uses thereof

    CN116693479B

  • Pentacyclic triterpenoid and application thereof as human intestine carboxylesterase inhibitor

    CN105713064A

  • 1-cyclohexylpyrazolone carboxylesterase 1 inhibitor as well as preparation and application thereof

    CN112279813A